BNP Paribas Arbitrage SA Has $5.50 Million Stock Position in Encompass Health Co. (NYSE:EHC)

BNP Paribas Arbitrage SA lifted its stake in Encompass Health Co. (NYSE:EHCGet Rating) by 541.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,299 shares of the company’s stock after acquiring an additional 71,154 shares during the period. BNP Paribas Arbitrage SA owned approximately 0.08% of Encompass Health worth $5,501,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in EHC. Whittier Trust Co. acquired a new stake in shares of Encompass Health in the fourth quarter worth $26,000. Signaturefd LLC grew its stake in shares of Encompass Health by 58.9% in the fourth quarter. Signaturefd LLC now owns 499 shares of the company’s stock worth $33,000 after acquiring an additional 185 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of Encompass Health by 103.1% in the fourth quarter. Parallel Advisors LLC now owns 532 shares of the company’s stock worth $35,000 after acquiring an additional 270 shares during the last quarter. First Horizon Advisors Inc. grew its stake in shares of Encompass Health by 100.8% in the third quarter. First Horizon Advisors Inc. now owns 741 shares of the company’s stock worth $39,000 after acquiring an additional 372 shares during the last quarter. Finally, UMB Bank N A MO acquired a new stake in shares of Encompass Health in the fourth quarter worth $59,000. Institutional investors and hedge funds own 91.70% of the company’s stock.

Shares of NYSE EHC opened at $64.09 on Friday. The stock has a market cap of $6.40 billion, a PE ratio of 16.39, a PEG ratio of 2.06 and a beta of 0.95. The business has a fifty day moving average of $68.98 and a two-hundred day moving average of $66.00. Encompass Health Co. has a 52-week low of $56.31 and a 52-week high of $88.13. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.26 and a current ratio of 1.26.

Encompass Health (NYSE:EHCGet Rating) last issued its quarterly earnings data on Wednesday, April 27th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. Encompass Health had a return on equity of 17.99% and a net margin of 7.51%. The company had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period last year, the business earned $1.05 earnings per share. The business’s revenue was up 8.4% on a year-over-year basis. Analysts predict that Encompass Health Co. will post 4.11 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 20th. Investors of record on Wednesday, July 13th will be issued a $0.28 dividend. The ex-dividend date of this dividend is Tuesday, July 12th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.75%. Encompass Health’s dividend payout ratio is 28.64%.

In other Encompass Health news, Director Kevin J. O’connor purchased 1,000 shares of the business’s stock in a transaction that occurred on Friday, May 6th. The stock was acquired at an average cost of $66.48 per share, with a total value of $66,480.00. Following the completion of the acquisition, the director now directly owns 3,436 shares of the company’s stock, valued at approximately $228,425.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.70% of the company’s stock.

EHC has been the subject of several research reports. Raymond James reduced their target price on Encompass Health from $90.00 to $80.00 and set a “strong-buy” rating for the company in a research report on Monday, February 7th. StockNews.com raised Encompass Health from a “hold” rating to a “buy” rating in a research report on Thursday. Truist Financial raised their target price on Encompass Health from $78.00 to $85.00 in a research report on Thursday, April 7th. TheStreet raised Encompass Health from a “c+” rating to a “b-” rating in a research report on Tuesday, March 15th. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on Encompass Health from $95.00 to $80.00 in a research report on Thursday, January 20th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $83.89.

About Encompass Health (Get Rating)

Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates in two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.

Featured Articles

Institutional Ownership by Quarter for Encompass Health (NYSE:EHC)

Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.